Welcome to our dedicated page for Burcon Nutrascience news (Ticker: BRCNF), a resource for investors and traders seeking the latest updates and insights on Burcon Nutrascience stock.
Burcon NutraScience Corporation (OTCQB: BRCNF; TSX: BU) regularly issues news updates that focus on its progress in plant-based protein innovation and commercialization. As a company that describes itself as a global technology leader in high-performance plant-based proteins for the food and beverage industry, its announcements often highlight developments in product performance, customer adoption, and financing activities.
News items from Burcon frequently cover milestones in commercial production and sales of its branded ingredients, such as Puratein® C canola protein, FavaPro™ fava protein, Peazazz® C pea protein, and Solatein™ sunflower protein. The company reports on first commercial production runs, initial commercial sales, and commercial sales orders for its next generation proteins, as well as the progression of customers from evaluation to purchase orders across its pea, canola, and fava platforms.
Burcon’s releases also include updates on scientific and technical validation of its ingredients. For example, the company has reported on a University of Guelph study in which its pea and sunflower proteins were found to outperform a competitor’s pea protein in a plant-based cheese application, with commentary on melt, stretch, and sensory attributes.
In addition, the company’s news flow features financial and corporate developments, including fiscal results, revenue trends from protein sales and contract manufacturing services, non-brokered private placements of convertible debentures, short-term loan agreements, and insider participation in financings. Governance-related announcements, such as board appointments and shareholder meeting results, are also part of its disclosures.
Investors and industry observers who follow Burcon’s news can track how the company describes its commercialization progress, customer pipeline, manufacturing partnerships, and capital structure as it advances its plant-based protein business.
Burcon (OTCQB: BRCNF) will hold a special shareholders meeting on February 20, 2026 (virtual) to seek disinterested shareholder approval to amend certain insider warrants. The company is extending the expiry of outstanding warrants totaling 1,544,249 common shares to June 30, 2027.
The Board has already amended Non-insider Warrants (effective February 19, 2026). Amendments for insider-held warrants are subject to disinterested shareholder approval at the Meeting. Management says exercising warrants could provide cash to accelerate capacity expansion.
Burcon (OTCQB: BRCNF) will host an investor conference call and webcast on Wednesday, February 11, 2026 at 5:00 p.m. ET to discuss fiscal 2026 third quarter results for the period ended December 31, 2025.
A press release with the Company's financial results will be issued prior to the call; a webcast link and archived replay will be available on Burcon's website under Presentations.
Burcon (OTCQB: BRCNF, TSX: BU) said it increased its non-brokered private placement of convertible debentures to an aggregate principal amount of up to $6.9 million on January 9, 2026, citing strong investor demand. Insiders and manufacturing partner owners have committed a minimum of $5.0 million. The TSX granted conditional approval pending compliance, including receipt of disinterested shareholder approval. Management reaffirmed a revenue target of more than $10 million for calendar 2026.
Burcon (OTCQB: BRCNF) closed the first tranche of a non‑brokered private placement of convertible debentures for $1.25 million, part of an aggregate financing of up to $6.3 million. Insiders and manufacturing partner owners committed at least $5.0 million in principal. The financing is conditionally approved by the TSX and the final tranche requires disinterested shareholder approval expected after a special meeting on February 20, 2026. Each debenture carries 15% interest, 48‑month maturity, and is convertible at $1.60 per share (with pre‑funded warrant option). Proceeds will fund production scale‑up, infrastructure planning, general corporate purposes and repay a short‑term loan.
Burcon (OTCQB: BRCNF) issued a shareholder letter highlighting 2025 commercial progress and plans for 2026 growth. The company reports calendar 2025 revenue of $1–3 million, validated its patented protein technologies at full commercial scale, and is selling ingredients across pea, canola, and fava platforms. Management reaffirmed a 2026 revenue target of more than $10 million and described a near‑term financing expected to support customer onboarding, increase throughput, and strengthen the balance sheet.
Burcon cites a pipeline of 200+ customer projects, a strategic manufacturing partnership with RE ProMan LLC, and insider support for the financing as evidence of commercial momentum entering 2026.
Burcon (OTCQB: BRCNF) announced that company insiders have increased their commitment to participate in the previously announced non-brokered private placement of convertible debentures. The company had earlier disclosed a minimum insider participation of $2.0 million in principal.
Because insider interest has grown since the November 12, 2025 announcement, Burcon said the larger insider participation could necessitate disinterested shareholder approval, and the Offering's close will be extended beyond the original on-or-about November 28, 2025 date while final terms are negotiated and required regulatory approvals (including TSX approval) are sought.
Burcon (OTCQB: BRCNF) reported fiscal Q2 results for the period ended September 30, 2025, highlighting first commercial production and sales of Puratein C canola and FavaPro fava proteins and expanded production of its pea protein.
Financials: Q2 revenue was $357,000 and six‑month revenue was $699,000 (up 783% and 152% vs prior year). Net loss was $7.1M (or $0.56/share); net cash used in operations was $4.6M. Cash on hand was $1.8M with a negative working capital of $8.2M. Post‑period items include >$500,000 in commercial orders, a $0.7M short‑term loan and a $4M convertible debenture offering.
Burcon (OTCQB: BRCNF) announced a non-brokered private placement of unsecured convertible debentures for up to $4.0 million, with insiders committing at least $2.0 million. Each debenture is $1,000, bears 15% interest payable at maturity, matures in 48 months, and is convertible at $2.27 per share. The company may prepay or force conversion if the TSX VWAP exceeds $4.54 for 14 consecutive trading days. Proceeds will fund inventory, production capacity, general corporate purposes and repay a short-term loan. Closing is expected on or about November 28, 2025, subject to TSX approval.
Separately, Burcon drew a related-party unsecured $700,000 loan on November 7, 2025 at 12% interest with a $7,000 commitment fee; the loan matures on the earlier of four months or closing of the Offering.
Burcon (OTCQB: BRCNF) will host an investor conference call and webcast on Wednesday, November 12, 2025 at 5:00 p.m. ET to discuss fiscal 2026 second quarter results for the period ended September 30, 2025. The company said its quarterly results will be released in a press release prior to the call.
CEO Kip Underwood reiterated a calendar 2025 revenue target of $1–3 million, citing production runs committed to multiple customers and growing protein sales expected to drive revenue acceleration and margin expansion into 2026. A webcast link and archived replay are available on Burcon's website under Presentations.
Burcon (OTCQB: BRCNF) announced a University of Guelph study (Oct 20, 2025) showing Burcon's Peazazz C pea protein and Solatein sunflower protein outperformed a leading competitor's pea protein in a plant-based mozzarella-style cheese formulation.
Researchers reported superior objective texture (cold hardness, shred efficacy, melting, stretch) and sensory results (taste, aroma, color). Peazazz C and Solatein are described as >90% purity, clean-label, hypoallergenic, non-GMO proteins with neutral/mild flavor profiles suitable for dairy-alternative applications.
FAQ
What is the current stock price of Burcon Nutrascience (BRCNF)?
What is the market cap of Burcon Nutrascience (BRCNF)?
